Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Tracy Nelson

Nurse Practitioner, Family Milwaukee, WI Nurse Practitioner

NPI 1346499738 CMS profile 10890690

2923 W Layton Ave, Milwaukee, WI 53221

Open in the dashboard

General payments

$24,480

534 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Tracy Nelson of Milwaukee, WI is reported in the CMS Open Payments database as having received $24,480 across 534 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,792 97
2024 General $2,725 106
2023 General $2,851 124
2022 General $5,124 88
2021 General $11,988 119

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Tracy Nelson
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to Tracy Nelson were reported at $1,792. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year Tracy Nelson Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $11,988 $124 $35–$379 $132
2022 $5,124 $141 $44–$430 $149
2023 $2,851 $154 $49–$476 $160
2024 $2,725 $165 $51–$504 $164
2025 $1,792 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Sun Pharmaceutical Industries Inc. $14,579 219 payments
  2. UCB, Inc. $4,406 33 payments
  3. AbbVie, Inc. $1,382 122 payments
  4. Genzyme Corporation $698 28 payments
  5. Janssen Biotech, Inc. $661 23 payments
  6. Arcutis Biotherapeutics, Inc. $431 17 payments
  7. Sanofi-Aventis U.S. LLC $361 5 payments
  8. Incyte Corporation $347 6 payments
  9. Lilly USA, LLC $343 17 payments
  10. E.R. Squibb & Sons, L.L.C. $281 12 payments
  11. Other $991 52 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $7,855 504 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $6,908 8 payments
  3. Honoraria $6,525 4 payments
  4. Consulting Fee $1,500 1 payment
  5. Education $898 13 payments
  6. Travel and Lodging $793 4 payments
Products named General payments · program years 2021–2025
  1. ILUMYA $14,131 202 payments
  2. Cimzia $3,214 12 payments
  3. DUPIXENT $953 32 payments
  4. SKYRIZI $904 82 payments
  5. TREMFYA $669 19 payments
  6. Bimzelx $392 20 payments
  7. OPZELURA $282 5 payments
  8. RINVOQ $273 23 payments
  9. SOTYKTU $233 10 payments
  10. TALTZ $212 14 payments
  11. Other $2,376 144 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 30 drugs

Part D claims

1,080

Median for Nurse Practitioner: 389

Drug cost

$1,484,617

Median for Nurse Practitioner: $21,885

Branded share of claims

23.1%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Dupixent Pen Dupilumab Brand 80 $316,079
Skyrizi Pen Risankizumab-Rzaa Brand 15 $314,445
Otezla Apremilast Brand 48 $247,195
Stelara Ustekinumab Brand 11 $242,712
Tremfya Guselkumab Brand 11 $146,782
Enbrel Mini Etanercept Brand 12 $93,725
Dupixent Syringe Dupilumab Brand 21 $82,124
Vtama Tapinarof Brand 12 $18,202
Ketoconazole Generic 180 $3,555
Clobetasol Propionate Generic 73 $2,545

The 10 drugs with the highest cost, of 30 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 19 billing codes

Paid by Medicare

$205,633

Of which drugs: $197,003

Medicare patients

131

Average age 77

Services billed

2,238

73 women, 58 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 45%
Chronic kidney disease 33%
Diabetes 27%
Ischemic heart disease 26%
Cancer 15%
Atrial fibrillation 13%
Heart failure 11%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, tildrakizumab, 1 mg J3245 Office 15 1,800 $197,000

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 16 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ILUMYA
  • Sun Pharmaceutical Industries Inc. $941
$941 — 1,800
DUPIXENT
  • GENZYME CORPORATION $186
  • SANOFI-AVENTIS U.S. LLC $95
  • Regeneron Healthcare Solutions, Inc. $18
$299 101 —
TREMFYA
  • Janssen Biotech, Inc. $275
$275 11 —
SKYRIZI
  • AbbVie, Inc. $272
$272 15 —
Bimzelx
  • UCB, Inc. $197
$197 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 16 in the dashboard with a free account

Records

534 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in Wisconsin

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record